Phase I study of TRXE 002 (Cantrixil) as a potential therapy for treatment-resistant cancer that has arisen within the abdomen or has metastasised there.
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs TRXE 002 (Primary)
- Indications Colorectal cancer; Malignant ascites; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
- 17 Mar 2016 According to a Novagen media release, this trial is scheduled to begin in the second half of 2016.
- 29 Jul 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a Novagen media release.